van der Tol A, Lameire N, Morton RL, Van Biesen W, Vanholder R. An international analysis of dialysis services reimbursement. Clin J Am Soc Nephrol. 2019;14(1):84–93.
Wong G, Howard K, Chapman JR, Chadban S, Cross N, Tong A, et al. Comparative survival and economic benefits of deceased donor kidney transplantation and dialysis in people with varying ages and co-morbidities. PLoS One. 2012;7(1):e29591.
Vanholder R, Annemans L, Brown E, Gansevoort R, Gout-Zwart JJ, Lameire N, et al. Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nat Rev Nephrol. 2017;13(7):393–409.
Cohen N, van de Craen D, Stamenovic A, Lagor C, Monitoring PH. The importance of home and community-based settings in population health management. Phillips Healthcare. 2013:1–11. https://leadingage.org/wp-content/uploads/drupal/The_importance_of_home_and_community_March_2013_1.pdf. Accessed 14 June 2022.
Ghods AJ, Savaj S. Iranian model of paid and regulated living-unrelated kidney donation. Clin J Am Soc Nephrol. 2006;1(6):1136–45.
Moradpour A, Hadian M, Tavakkoli M. Economic evaluation of end stage renal disease treatments in Iran. Clin Epidemiol Glob Health. 2020;8(1):199–204.
Just PM, De Charro FT, Tschosik EA, Noe LL, Bhattacharyya SK, Riella MC. Reimbursement and economic factors influencing dialysis modality choice around the world. Nephrol Dial Transplant. 2008;23(7):2365–73.
Lin M-Y, Cheng L-J, Chiu Y-W, Hsieh H-M, Wu P-H, Lin Y-T, et al. Effect of national pre-ESRD care program on expenditures and mortality in incident dialysis patients: a population-based study. PLoS One. 2018;13(6):e0198387.
Erickson KF, Winkelmayer WC, Chertow GM, Bhattacharya J. Medicare reimbursement reform for provider visits and health outcomes in patients on hemodialysis. Forum Health Econ Policy. 2014;17(1):53–77.
Swaminathan S, Mor V, Mehrotra R, Trivedi AN. Effect of Medicare dialysis payment reform on use of erythropoiesis stimulating agents. Health Serv Res. 2015;50(3):790–808.
Fuller DS, Bieber BA, Pisoni RL, Li Y, Morgenstern H, Akizawa T, et al. International comparisons to assess effects of payment and regulatory changes in the United States on anemia practice in patients on hemodialysis: the dialysis outcomes and practice patterns study. J Am Soc Nephrol. 2016;27(7):2205–15.
Hirth RA, Turenne MN, Wheeler JR, Nahra TA, Sleeman KK, Zhang W, et al. The initial impact of Medicare's new prospective payment system for kidney dialysis. Am J Kidney Dis. 2013;62(4):662–9.
Busink E, Canaud B, Schröder-Bäck P, Paulus AT, Evers SM, Apel C, et al. Chronic kidney disease: exploring value-based healthcare as a potential viable solution. Blood Purif. 2019;47(1–3):156–65.
Prospective Payment Systems - General Information [https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ProspMedicareFeeSvcPmtGen]. Accessed 14 June 2022.
Dor A, Pauly MV, Eichleay MA, Held PJ. End-stage renal disease and economic incentives: the international study of health care organization and financing (ISHCOF). Int J Health Care Finance Econ. 2007;7(2):73–111.
Mentari EK, DeOreo PB, O’Connor AS, Love TE, Ricanati ES, Sehgal AR. Changes in Medicare reimbursement and patient-nephrologist visits, quality of care, and health-related quality of life. Am J Kidney Dis. 2005;46(4):621–7.
Van Biesen W, Lameire N, Peeters P, Vanholder R. Belgium’s mixed private/public health care system and its impact on the cost of end-stage renal disease. Int J Health Care Finance Econ. 2007;7(2):133–48.
Shifting the paradigm of Diaverum Portugal’s renal care services Towards integrated dialysis care. [https://global.diaverum.com/globalassets/why-diaverum/value-based-renal-care/lse-final-version-29-june-2020.pdf]. Accessed 14 June 2022.
Hippen BE, Maddux FW. Integrating kidney transplantation into value-based care for people with renal failure. Am J Transplant. 2018;18(1):43–52.
Hussey PS, Ridgely MS, Rosenthal MB. The PROMETHEUS bundled payment experiment: slow start shows problems in implementing new payment models. Health Aff. 2011;30(11):2116–24.
Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–73.
Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32.
Chang R-E, Tsai Y-H, Myrtle RC. Assessing the impact of budget controls on the prescribing behaviours of physicians treating dialysis-dependent patients. Health Policy Plan. 2015;30(9):1142–51.
Trachtenberg AJ, Quinn AE, Ma Z, Klarenbach S, Hemmelgarn B, Tonelli M, et al. Association between change in physician remuneration and use of peritoneal dialysis: a population-based cohort analysis. Can Med Assoc Open Access J. 2020;8(1):E96–E104.
Wang C, Kane R, Levenson M, Kelman J, Wernecke M, Lee J-Y, et al. Association between changes in CMS reimbursement policy and drug labels for erythrocyte-stimulating agents with outcomes for older patients undergoing hemodialysis covered by fee-for-service Medicare. JAMA Intern Med. 2016;176(12):1818–25.
Spoendlin J, Schneeweiss S, Tsacogianis T, Paik JM, Fischer MA, Kim SC, et al. Association of Medicare's bundled payment reform with changes in use of vitamin D among patients receiving maintenance hemodialysis: an interrupted time-series analysis. Am J Kidney Dis. 2018;72(2):178–87.
Hasegawa T, Bragg-Gresham JL, Pisoni RL, Robinson BM, Fukuhara S, Akiba T, et al. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin. Kidney Int. 2011;79(3):340–6.
Brunelli SM, Monda KL, Burkart JM, Gitlin M, Neumann PJ, Park GS, et al. Early trends from the study to evaluate the prospective payment system impact on small dialysis organizations (STEPPS). Am J Kidney Dis. 2013;61(6):947–56.
Chang R-E, Hsieh C-J, Myrtle RC. The effect of outpatient dialysis global budget cap on healthcare utilization by end-stage renal disease patients. Soc Sci Med. 2011;73(1):153–9.
Erickson KF, Winkelmayer WC, Chertow GM, Bhattacharya J. Effects of physician payment reform on provision of home dialysis. Am J Manag Care. 2016;22(6):e215.
Haarsager J, Krishnasamy R, Gray NA. Impact of pay for performance on access at first dialysis in Queensland. Nephrology. 2018;23(5):469–75.
Erickson KF, Winkelmayer WC, Chertow GM, Bhattacharya J. Hemodialysis hospitalizations and readmissions: the effects of payment reform. Am J Kidney Dis. 2017;69(2):237–46.
Zhang Q, Thamer M, Kshirsagar O, Zhang Y. Impact of the end stage renal disease prospective payment system on the use of peritoneal dialysis. Kidney Int Rep. 2017;2(3):350–8.
Desai AA, Bolus R, Nissenson A, Chertow GM, Bolus S, Solomon MD, et al. Is there “cherry picking” in the ESRD program? Perceptions from a Dialysis provider survey. Clin J Am Soc Nephrol. 2009;4(4):772–7.
Wang V, Coffman CJ, Sanders LL. Lee S-YD, Hirth RA, Maciejewski ML: Medicare’s new prospective payment system on facility provision of peritoneal dialysis. Clin J Am Soc Nephrol. 2018;13(12):1833–41.
Young EW, Kapke A, Ding Z, Baker R, Pearson J, Cogan C, et al. Peritoneal dialysis patient outcomes under the medicare expanded dialysis prospective payment system. Clin J Am Soc Nephrol. 2019;14(10):1466–74.
Sloan CE, Coffman CJ, Sanders LL, Maciejewski ML, Lee S-YD, Hirth RA, et al. Trends in peritoneal dialysis use in the United States after Medicare payment reform. Clin J Am Soc Nephrol. 2019;14(12):1763–72.
Norouzi S, Zhao B, Awan A, Winkelmayer WC, Ho V, Erickson KF. Bundled payment reform and dialysis facility closures in ESKD. J Am Soc Nephrol. 2020;31(3):579–90.
Kleophas W, Karaboyas A, Li Y, Bommer J, Reichel H, Walter A, et al. Changes in dialysis treatment modalities during institution of flat rate reimbursement and quality assurance programs. Kidney Int. 2013;84(3):578–84.
Spiegel DM, Khan I, Krishnan M, Mayne TJ. Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008. Am J Kidney Dis. 2010;55(1):113–20.
Monda KL, Joseph PN, Neumann PJ, Bradbury BD, Rubin RJ. Comparative changes in treatment practices and clinical outcomes following implementation of a prospective payment system: the STEPPS study. BMC Nephrol. 2015;16(1):1–10.
Wetmore JB, Tzivelekis S, Collins AJ, Solid CA. Effects of the prospective payment system on anemia management in maintenance dialysis patients: implications for cost and site of care. BMC Nephrol. 2016;17(1):1–9.
Pirkle JL Jr, Paoli CJ, Russell G, Petersen J, Burkart J. Hemoglobin stability and patient compliance with darbepoetin alfa in peritoneal dialysis patients after the implementation of the prospective payment system. Clin Ther. 2014;36(11):1665–74.
Lin E, Cheng XS, Chin K-K, Zubair T, Chertow GM, Bendavid E, et al. Home dialysis in the prospective payment system era. J Am Soc Nephrol. 2017;28(10):2993–3004.
McFarlane PA, Pisoni RL, Eichleay MA, Wald R, Port FK, Mendelssohn D. International trends in erythropoietin use and hemoglobin levels in hemodialysis patients. Kidney Int. 2010;78(2):215–23.
Thamer M, Zhang Y, Kaufman J, Kshirsagar O, Cotter D, Hernán MA. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status. Am J Nephrol. 2014;40(6):554–60.
Mendelssohn DC, Langlois N, Blake PG. Peritoneal dialysis in Ontario: a natural experiment in physician reimbursement methodology. Perit Dial Int. 2004;24(6):531–7.
Hornberger J, Hirth RA. Financial implications of choice of dialysis type of the revised Medicare payment system: an economic analysis. Am J Kidney Dis. 2012;60(2):280–7.
Pisoni RL, Zepel L, Port FK, Robinson BM. Trends in US vascular access use, patient preferences, and related practices: an update from the US DOPPS practice monitor with international comparisons. Am J Kidney Dis. 2015;65(6):905–15.
Tentori F, Fuller DS, Port FK, Bieber BA, Robinson BM, Pisoni RL. The DOPPS practice monitor for US dialysis care: potential impact of recent guidelines and regulatory changes on management of mineral and bone disorder among US hemodialysis patients. Am J Kidney Dis. 2014;63(5):851–4.
Park H, Rascati KL, Keith MS. Managing oral phosphate binder medication expenditures within the Medicare bundled end-stage renal disease prospective payment system: economic implications for large US dialysis organizations. J Manag Care Spec Pharm. 2015;21(6):507–14.
Pisoni RL, Fuller DS, Bieber BA, Gillespie BW, Robinson BM. The DOPPS practice monitor for US dialysis care: trends through august 2011. Am J Kidney Dis. 2012;60(1):160–5.
Vanholder R, Davenport A, Hannedouche T, Kooman J, Kribben A, Lameire N, et al. Reimbursement of dialysis: a comparison of seven countries. J Am Soc Nephrol. 2012;23(8):1291–8.
Ponce P, Marcelli D, Guerreiro A, Grassmann A, Gonçalves C, Scatizzi L, et al. Converting to a capitation system for dialysis payment–the Portuguese experience. Blood Purif. 2012;34(3–4):313–24.
Maddux FW. Impact of the bundled end-stage renal disease payment system on patient care. Blood Purif. 2012;33(1–3):107–11.
Robinson B, Fuller D, Zinsser D, Albert J, Gillespie B, Tentori F, et al. The Dialysis outcomes and practice patterns study (DOPPS) practice monitor: rationale and methods for an initiative to monitor the new US bundled dialysis payment system. Am J Kidney Dis. 2011;57(6):822–31.
Golper TA, Guest S, Glickman JD, Turk J, Pulliam JP. Home dialysis in the new USA bundled payment plan: implications and impact. Perit Dial Int. 2011;31(1):12–6.
Wish JB. Past, present, and future of chronic kidney disease anemia management in the United States. Adv Chronic Kidney Dis. 2009;16(2):101–8.
Naito H. The Japanese health-care system and reimbursement for dialysis. Perit Dial Int. 2006;26(2):155–61.
Swaminathan S, Mor V, Mehrotra R, Trivedi A. Medicare’s payment strategy for end-stage renal disease now embraces bundled payment and pay-for-performance to cut costs. Health Aff. 2012;31(9):2051–8.
Rivara MB, Mehrotra R. The changing landscape of home dialysis in the United States. Curr Opin Nephrol Hypertens. 2014;23(6):586.
Fuller DS, Pisoni RL, Bieber BA, Port FK, Robinson BM. The DOPPS practice monitor for US dialysis care: update on trends in anemia management 2 years into the bundle. Am J Kidney Dis. 2013;62(6):1213–6.
Piccoli GB, Cabiddu G, Breuer C, Jadeau C, Testa A, Brunori G. Dialysis reimbursement: what impact do different models have on clinical choices? J Clin Med. 2019;8(2):276.
Durand-Zaleski I, Combe C, Lang P. International study of health care organization and financing for end-stage renal disease in France. Int J Health Care Finance Econ. 2007;7(2):171–83.
Pontoriero G, Pozzoni P, Vecchio LD, Locatelli F. International study of health care organization and financing for renal replacement therapy in Italy: an evolving reality. Int J Health Care Finance Econ. 2007;7(2):201–15.
Nicholson T, Roderick P. International study of health care organization and financing of renal services in England and Wales. Int J Health Care Finance Econ. 2007;7(4):283–99.
Luño J. The organization and financing of end-stage renal disease in Spain. Int J Health Care Finance Econ. 2007;7(4):253–67.
Fukuhara S, Yamazaki C, Hayashino Y, Higashi T, Eichleay MA, Akiba T, et al. The organization and financing of end-stage renal disease treatment in Japan. Int J Health Care Finance Econ. 2007;7(2):217–31.
Kleophas W, Reichel H. International study of health care organization and financing: development of renal replacement therapy in Germany. Int J Health Care Finance Econ. 2007;7(2):185–200.
Wikström B, Fored M, Eichleay MA, Jacobson SH. The financing and organization of medical care for patients with end-stage renal disease in Sweden. Int J Health Care Finance Econ. 2007;7(4):269–81.
Ashton T, Marshall MR. The organization and financing of dialysis and kidney transplantation services in New Zealand. Int J Health Care Finance Econ. 2007;7(4):233–52.
Manns BJ, Mendelssohn DC, Taub KJ. The economics of end-stage renal disease care in Canada: incentives and impact on delivery of care. Int J Health Care Finance Econ. 2007;7(2):149–69.
Hirth RA. The organization and financing of kidney dialysis and transplant care in the United States of America. Int J Health Care Finance Econ. 2007;7(4):301–18.
Harris A. The organization and funding of the treatment of end-stage renal disease in Australia. Int J Health Care Finance Econ. 2007;7(2):113–32.
Hirth R, Wheeler J, Messana J, Turenne M, Tedeschi P, Sleeman K, et al. End stage renal disease payment system: results of research on case-mix adjustment for an expanded bundle. Ann Arbor: University of Michigan Kidney Epidemiology and Cost Center; 2008.
Andrawis JP, Koenig KM, Bozic KJ. Bundled payment care initiative: How this all started. Semin Arthroplast. 2016;27(3):188–92.
Kuwabara H, Fushimi K. The impact of a new payment system with case-mix measurement on hospital practices for breast cancer patients in Japan. Health Policy. 2009;92(1):65–72.
Busse R, Geissler A, Aaviksoo A, Cots F, Häkkinen U, Kobel C, et al. Diagnosis related groups in Europe: moving towards transparency, efficiency, and quality in hospitals? BMJ. 2013;1–7.
Mettang T. Changes in dialysis reimbursement regulations in Germany. Perit Dial Int. 2004;24(6):526–7.
Davis CM III, Swenson ER, Lehman TM, Haas DA. Economic impact of outpatient Medicare total knee arthroplasty at a tertiary care academic medical center. J Arthroplasty. 2020;35(6):S37–41.
de Bakker DH, Struijs JN, Baan CA, Raams J, de Wildt J-E, Vrijhoef HJ, et al. Early results from adoption of bundled payment for diabetes care in the Netherlands show improvement in care coordination. Health Aff. 2012;31(2):426–33.
Humbyrd CJ, Wu SS, Trujillo AJ, Socal MP, Anderson GF. Patient selection after mandatory bundled payments for hip and knee replacement: limited evidence of lemon-dropping or cherry-picking. JBJS. 2020;102(4):325–31.
McLawhorn AS, Buller LT. Bundled payments in total joint replacement: keeping our care affordable and high in quality. Curr Rev Musculoskelet Med. 2017;10(3):370–7.
Hollenbeak CS, Rubin RJ, Tzivelekis S, Stephens JM. Trends in prevalence of patient case-mix adjusters used in the Medicare dialysis payment system. Nephrol News Issues. 2015;29(6):24–27, 31.
Markovitz AA, Ellimoottil C, Sukul D, Mullangi S, Chen LM, Nallamothu BK, et al. Risk adjustment may lessen penalties on hospitals treating complex cardiac patients under Medicare’s bundled payments. Health Aff. 2017;36(12):2165–74.